Saili Medical issued a change announcement. The company is concerned that the market is paying a lot of attention to the innovative drug business recently. Huajiyuan Biotech, a joint venture of the company, is a participating company invested by the company in January 2020. It holds 15.61% of its shares, with an investment amount of 10.666 million yuan. Huajiyuan Biotech's 2024 revenue is 26,800 yuan, and net profit is 2.3823 million yuan. Its therapeutic antihypertensive vaccine project, HJY-ATRQβ-001, has completed proof-of-concept research and pre-clinical research, and was accepted by the State Drug Administration on June 6, 2025. It still needs to go through phase I and phase II clinical trials. There is still significant uncertainty about whether the trial will be successful. The above investments currently have little impact on the company's main business. Investors are kindly requested to pay attention to related risks, make rational decisions, and invest prudently.

Saili Medical issued a change announcement. The company is concerned that the market is paying a lot of attention to the innovative drug business recently. Huajiyuan Biotech, a joint venture of the company, is a participating company invested by the company in January 2020. It holds 15.61% of its shares, with an investment amount of 10.666 million yuan. Huajiyuan Biotech's 2024 revenue is 26,800 yuan, and net profit is 2.3823 million yuan. Its therapeutic antihypertensive vaccine project, HJY-ATRQβ-001, has completed proof-of-concept research and pre-clinical research, and was accepted by the State Drug Administration on June 6, 2025. It still needs to go through phase I and phase II clinical trials. There is still significant uncertainty about whether the trial will be successful. The above investments currently have little impact on the company's main business. Investors are kindly requested to pay attention to related risks, make rational decisions, and invest prudently.